0H19 Stock Overview
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Orexo AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr16.08 |
| 52 Week High | kr19.02 |
| 52 Week Low | kr8.99 |
| Beta | 0.58 |
| 1 Month Change | 9.24% |
| 3 Month Change | 15.43% |
| 1 Year Change | 15.43% |
| 3 Year Change | -62.67% |
| 5 Year Change | -77.05% |
| Change since IPO | -72.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0H19 | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -2.4% | -1.3% | -0.9% |
| 1Y | 15.4% | -5.5% | -1.8% |
Return vs Industry: 0H19 exceeded the UK Pharmaceuticals industry which returned -5.5% over the past year.
Return vs Market: 0H19 exceeded the UK Market which returned -1.8% over the past year.
Price Volatility
| 0H19 volatility | |
|---|---|
| 0H19 Average Weekly Movement | 5.5% |
| Pharmaceuticals Industry Average Movement | 8.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0H19 has not had significant price volatility in the past 3 months.
Volatility Over Time: 0H19's weekly volatility has decreased from 14% to 5% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 116 | Nikolaj Sorensen | www.orexo.com |
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis.
Orexo AB (publ) Fundamentals Summary
| 0H19 fundamental statistics | |
|---|---|
| Market cap | kr543.61m |
| Earnings (TTM) | -kr128.30m |
| Revenue (TTM) | kr638.80m |
0.9x
P/S Ratio-4.2x
P/E RatioIs 0H19 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0H19 income statement (TTM) | |
|---|---|
| Revenue | kr638.80m |
| Cost of Revenue | kr88.90m |
| Gross Profit | kr549.90m |
| Other Expenses | kr678.20m |
| Earnings | -kr128.30m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | -3.72 |
| Gross Margin | 86.08% |
| Net Profit Margin | -20.08% |
| Debt/Equity Ratio | 761.3% |
How did 0H19 perform over the long term?
See historical performance and comparison